PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Oct 10, 2013
SOUTH PLAINFIELD, NJ – October 10, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that the following two posters will be presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah, on October 17-19: ? The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients w...
Oct 1, 2013
SOUTH PLAINFIELD, NJ – October 1, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Mr. Martin Rexroad as Senior Vice President, Human Resources and Mr. R.A. Session II as Vice President, Corporate Development, both reporting to Ms. Cláudia Hirawat, President of PTC Therapeutics, Inc. In addition, Dr. Jay Bar...
Sep 30, 2013
SOUTH PLAINFIELD, NJ – September 30, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it was included on the list of quarterly initial public offering additions to the Russell 2000® Index to be effective at the close of the U.S. market on September 30, 2013."We are very pleased to be included in the Russell 20...
Sep 27, 2013
SOUTH PLAINFIELD, NJ – September 27, 2013 –PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in two upcoming investor conferences. ? Management will participate in a roundtable discussion at the Lazard Capital Markets' GenomeRX: Genes as Drugs Workshop on Tuesday, October 1 at 4:00 pm ET in New...
Sep 25, 2013
SOUTH PLAINFIELD, NJ – September 25, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that four posters will be presented at the 18th International World Muscle Society Congress (WMS) in Asilomar, California, on October 1-5. The following posters will be presented on October 3 from 14:30 - 16:00 during Dystrophinopathy pharmco and p...
Sep 18, 2013
SOUTH PLAINFIELD, NJ – September 18, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that two abstracts have been accepted for the 10th European Pediatric Neurology Society Congress (EPNS) in Brussels, Belgium, on September 25-28. ? Design of a confirmatory phase 3, multicenter, randomized, double-blind, placebo-controlled study ...
Aug 29, 2013
SOUTH PLAINFIELD, NJ – August 29, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in following conferences in September: ? Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, will participate in a panel at the Citi 8th Annual Biotech Conference in Boston on Wednesday, September 4 ...
Aug 26, 2013
SOUTH PLAINFIELD, NJ – August 26, 2013 – Data published in the medical journal Muscle & Nerve demonstrate the clinical meaningfulness of the 6-minute walk test (6MWT) as a primary endpoint to measure disease progression and walking ability in ambulatory Duchenne muscular dystrophy (DMD) trials. The research also showed that a range of 20 ...
Aug 12, 2013
SOUTH PLAINFIELD, NJ - August 12, 2013 - PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced financial and corporate results for the quarter ended June 30, 2...
Aug 8, 2013
SOUTH PLAINFIELD, NJ – August 8, 2013 – PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation. The achievement of the milestone triggers a $10 million payment to PTC from Roche. "We are excited about thi...
Page: FirstPrevious ...
22
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue